Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given a $5.00 Price Target at Jefferies Group LLC
Jefferies Group LLC set a $5.00 target price on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in a research note released on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently issued reports on XENE. Canaccord Genuity reaffirmed a buy rating and set a $5.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. Zacks Investment Research raised Xenon Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, July 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Xenon Pharmaceuticals currently has a consensus rating of Buy and an average target price of $11.88.
Xenon Pharmaceuticals (NASDAQ XENE) opened at 3.05 on Friday. The firm’s market capitalization is $54.89 million. The firm’s 50-day moving average is $3.46 and its 200-day moving average is $5.32. Xenon Pharmaceuticals has a 12 month low of $2.85 and a 12 month high of $9.95.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.03. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.38 million. Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. On average, equities research analysts expect that Xenon Pharmaceuticals will post ($0.76) EPS for the current year.
In other Xenon Pharmaceuticals news, insider Value Fund L. P. Biotechnology acquired 358,698 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, June 7th. The stock was bought at an average cost of $3.81 per share, with a total value of $1,366,639.38. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Value Fund L. P. Biotechnology acquired 20,411 shares of Xenon Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The stock was acquired at an average cost of $4.00 per share, with a total value of $81,644.00. The disclosure for this purchase can be found here. Insiders bought 490,978 shares of company stock valued at $1,891,534 over the last three months. 9.40% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the stock. Endurant Capital Management LP acquired a new stake in Xenon Pharmaceuticals during the first quarter valued at $1,363,000. Sabby Management LLC acquired a new stake in Xenon Pharmaceuticals during the first quarter valued at $1,186,000. Renaissance Technologies LLC boosted its stake in Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock valued at $868,000 after buying an additional 102,890 shares in the last quarter. K2 Principal Fund L.P. boosted its stake in Xenon Pharmaceuticals by 104.4% in the first quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 59,747 shares in the last quarter. Finally, KCG Holdings Inc. acquired a new stake in Xenon Pharmaceuticals during the first quarter valued at $122,000. 56.01% of the stock is owned by institutional investors.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.